[Anne Schley]

Will future clinical trials be able to utilize the local health systems to track background incidence? What are the down sides of reaching out?

Discussion

[Navita Jain]

Such a good point Anne! I wonder what local health systems would see as some of the challenges. I imagine how data is aggregated and reported will have a big impact on using background incidence, but would be interested in hearing more from experts on this. And wonder if this was discussed during the recent Enterprise webinars (https://vaccineenterprise.org/hiv-prevention-clinical-trial-design-of-the-future/)